Abstract:Background and Objectives Ezetimibe/simvastatin combination tablet has been approved for the treatment of high low-density lipoprotein cholesterol (LDL-C) levels in patients with primary hypercholesterolaemia or mixed hypercholesterolaemia as adjunctive therapy to diet, when diet alone is insufficient in lowering cholesterol. The aims of this study were to assess the pharmacokinetics and safety of an ezetimibe/simvastatin combination tablet after oral single-dose administration in healthy Chinese subjects including sex-related differences in pharmacokinetics. Methods This was an open-label, single-dose study. Twelve healthy subjects (six males and six females) received a single dose of an ezetimibe/simvastatin combination tablet (ezetimibe 10 mg and simvastatin 40 mg). The pharmacokinetic parameters for ezetimibe and simvastatin were assessed by determining total ezetimibe, free ezetimibe, simvastatin and simvastatin acid concentrations using a validated liquid chromatography–tandem mass spectrometry method. Safety was evaluated by monitoring adverse events, laboratory assays, vital signs, physical examinations and 12-lead electrocardiograms. Results The pharmacokinetic parameters (mean ± SD) for total ezetimibe and free ezetimibe following a single dose were: maximum plasma drug concentration (C max ) 81.56 ± 26.62 and 9.40 ± 6.17 ng/mL; time to reach C max (t max ) 0.93 ± 0.30 and 1.25 ± 1.27 h; elimination half-life (t ½ ) 24.32 ± 13.27 and 18.90 ± 9.66 h, and mean area under the plasma concentration–time curve from time zero to the time of the last measurable concentration (AUC last ) 579.06 ± 241.45 and 126.01 ± 69.01 ng·h/mL, respectively. The pharmacokinetic parameters (mean ± SD) for simvastatin and simvastatin acid following a single dose were: C max 11.92 ± 5.50 and 3.37 ± 1.78 ng/mL, t max 0.98 ± 0.28 and 3.73 ± 1.68 h, t ½ 4.19 ± 1.81 and 7.65 ± 7.96 h, and mean AUC last 33.63 ± 20.41 and 32.50 ± 18.79 ng·h/mL. Higher AUC last and AUC from time zero to infinity (AUC ∞ ), and lower apparent total body clearance of drug from plasma after oral administration (CL/F) for total ezetimibe and free ezetimibe were observed in female subjects compared with those in male subjects. There were no differences between the pharmacokinetic parameters of simvastatin and simvastatin acid for female and male subjects in the study. Conclusion Ezetimibe/simvastatin combination tablet has a generally favourable safety and tolerability profile in healthy Chinese subjects. A statistically significant difference with regard to sex in the pharmacokinetics of ezetimibe was observed. Sex had no effect on the pharmacokinetics of simvastatin and simvastatin acid.

Population pharmacokinetics study of simvastatin in hemodialysis patients

Population Pharmacokinetics of Vancomycin in Kidney Transplant Recipients: Model Building and Parameter Optimization.

Physiologically Based Pharmacokinetic-Pharmacodynamic Evaluation of Meropenem in CKD and Hemodialysis Individuals

Simvastatin Pharmacokinetics in Healthy Chinese Subjects and Its Relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 Polymorphisms.

Population Pharmacokinetic Characteristics of Sirolimus in Healthy Chinese Subjects and Renal Transplant Patients

Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study

Effects of Administration and Intensity of Statins on Mortality in Patients Undergoing Hemodialysis

A simulation study of sampling time point designing for therapeutic drug monitoring based on a population pharmacokinetic model

Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension

Pharmacokinetics and Safety of Ezetimibe/Simvastatin Combination Tablet

Initial Dosage Regimens Of Vancomycin For Chinese Adult Patients Based On Population Pharmacokinetic Analysis

LC -ESI- MS/MS Determination of Simvastatin in Human Plasma

Influences of renal function descriptors on population pharmacokinetic modeling of vancomycin in Chinese adult patients

Time-dependent Clearance of Cyclosporine in Adult Renal Transplant Recipients: A Population Pharmacokinetic Perspective

Population Pharmacokinetic and Pharmacodynamic of Atorvastatin in Chinese Lung Transplant Recipients

The solutes removal capability in four different membrane dialyzers in hemodialysis maintenance patients

Solutes Removal Characteristics at Various Effluent Rates During Different Continuous Renal Replacement Therapy Modalities

Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure

Pharmacokinetics and pharmacodynamics of sacubitril/valsartan in peritoneal dialysis patients

Population Pharmacokinetics Of Cyclosporine In Clinical Renal Transplant Patients

Study on the Effect of Fenofibrate to Pharmacokinetics of Simvastatin in Healthy Volunteers